Survival outcomes in all evaluable patients. (A) PFS (6 events). (B) OS (3 events). Three died without progression before death (accidental fall at month 7; unexpected sudden cardiac death with no autopsy at month 8 (treatment relationship unknown; Hodgkin lymphoma Epstein-Barr virus–associated hemophagocytosis at month 23). Three further patients experienced progression (at months 11, 35, and 39). Following progression, patients could continue to be followed for OS. After 42 months, follow-up for survival outcomes was censored due to the low numbers of patients at risk. One clinical relapse occurred at month 38, 22 months after the end of treatment; the patient had CR (confirmed by blinded review) with undetectable MRD at month 16, and concomitantly initiated surgical and radiotherapy for epidermoid gum cancer.